Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The gradual deterioration of cognitive functions in Alzheimer's disease is paralleled by a hierarchical progression of amyloid-beta and tau brain pathology. Recent findings indicate that toxic oligomers of amyloid-beta may cause propagation of pathology in a prion-like manner, although the underlying mechanisms are incompletely understood. Here we show that small extracellular vesicles, exosomes, from Alzheimer patients' brains contain increased levels of amyloid-beta oligomers and can act as vehicles for the neuron-to-neuron transfer of such toxic species in recipient neurons in culture. Moreover, blocking the formation, secretion or uptake of exosomes was found to reduce both the spread of oligomers and the related toxicity. Taken together, our results imply that exosomes are centrally involved in Alzheimer's disease and that they could serve as targets for development of new diagnostic and therapeutic principles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, in damaged environments, like AD, exosomes are involved in the transportation of damaging proteins like Aβ and Tau [116].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [116]
The cited source says what the claim attributes to it.
In the citing paper
“A previous study has shown that sEVs isolated from the brains of AD patients contain elevated levels of Aβ oligomers [141].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [141]
The cited source says what the claim attributes to it.
In the citing paper
“These EVs have been discovered as possible transporters for transferring toxic protein species from neuron to neuron, as has been shown in vitro.”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [141]
The cited source says what the claim attributes to it.
In the citing paper
“oAβ42 has been detected within neuronal exosomes.”
From The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates (2020) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Data from cells treated with these exosomes also revealed that the exosomes facilitated delivery of oAβ42 and induced toxic effects [24].”
From The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ngolab, J., Trinh, I., Rockenstein, E., Mante, M., Florio, J., Trejo, M., Masliah, D., Adame, A., Masliah, E., & Rissman, R. A. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0445-5 · Cited by 200 · cited 1×
“These findings suggest that exosomes might be the main mediator of the pathogenic progression in AD as was recently suggested for dementia with Lewy bodies [41].”
BackgroundRetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature Reviews Immunology · doi:10.1038/nri855 · Cited by 5,346 · cited 2×
“It has been suggested that exosomal release may provide an alternative disposal mechanism to lysosomal degradation of oAβ [5] or other proteins that are resistant to degradation [55].”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“The nature of the propagating species has not been established, although several studies have indicated a particularly pathogenic role of soluble oAβ on synaptic and cellular functions and structure [13, 32, 50, 60].”
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591 · cited 1×
“1 3 Aß, tau and α-synuclein [12, 17, 46, 59] and can propagate tau pathology [4].”
BackgroundAlzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343 · cited 2×
“Accordingly, exosomes from blood [22], CSF [17, 49] and cell cultures [46] have been shown to contain monomeric Aβ and tau, but so far, no study has addressed the presence of oAβ in exosomes from human AD brains.”
BackgroundAxonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer’s Disease
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S., et al. (2005) · Science · doi:10.1126/science.1105681 · Cited by 1,214 · cited 1×
“Here dystrophic neurites with neurite beading and loss of neurite branching were identified, known early signs of neurodegeneration [51].”
Background
Research works printed but not linked: 1
- Tucker S, Möller C, Tegerstedt K, Lord A, Laudon H, Sjödahl J, Söderberg L, Spens E, Sahlin C, Waara ER et al (2015) The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. JAD 43:575–588. https://doi.org/10.3233/JAD-140741 · DOI · Paper page
Cited by
Items 101–200 of 530
Filannino, F. M., Panaro, M. A., Benameur, T., Pizzolorusso, I., & Porro, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031629 · Cited by 60
Diagnostic and Therapeutic Potential of Exosomes in Neurodegenerative Diseases
Gao, P., Li, X., Du, X., Liu, S., & Xu, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.790863 · Cited by 60
Chen, C., Bao, Y., Lü, X., Jiang, C., Guo, Y., Tong, S., Zhang, J., Chen, L., & Mao, Y. Q. (2023) · Advanced Science · doi:10.1002/advs.202304025 · Cited by 80
Extraction of Extracellular Vesicles from Whole Tissue
Hurwitz, S. N., Olcese, J., & Meckes, D. G. (2019) · Journal of Visualized Experiments · doi:10.3791/59143 · Cited by 64
Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease
Li, T.-R., Wang, X.-N., Sheng, C., Li, Y.-X., Li, F. Z.-T., Sun, Y., & Han, Y. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111175 · Cited by 60
3D-visualization of amyloid-β oligomer interactions with lipid membranes by cryo-electron tomography
Tian, Y., Liang, R., Kumar, A., Szwedziak, P., & Viles, J. H. (2021) · Chemical Science · doi:10.1039/d0sc06426b · Cited by 64
Liao, K., Niu, F., Hu, G., Yang, L., Dallon, B., Villarreal, D., & Buch, S. (2020) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12027 · Cited by 59
“…be released by most cell types and have been implicated to play a key role in various neurodegenerative diseases, such as Alzheimer’s Disease (Sardar Sinha et al., 2018), Parkinson’s disease (Shi et al., 2014), Amyotrophic Lateral Sclerosis (Roy, Saucier, O’connell, & Morin, 2019) and…”
Gomes, P., Tzouanou, F., Skolariki, K., Vamvaka-Iakovou, A., Noguera-Ortiz, C., Tsirtsaki, K., Waites, C. L., Vlamos, P., Sousa, N., Costa-Silva, B., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114183 · Cited by 55
“Similarly, EVs derived from AD patients’ brain that contained A β oligomers were found to transfer such toxic A β species to recipient neurons in culture-inducing toxicity (Sardar Sinha et al., 2018).”
InfluentialExtracellular Vesicles: Techniques and Biomedical Applications Related to Single Vesicle Analysis
Zhang, J., Wu, J., Wang, G., He, L., Zheng, Z., Wu, M., & Zhang, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c03172 · Cited by 60
Microglial Extracellular Vesicles as Vehicles for Neurodegeneration Spreading
Aires, I. D., Ribeiro‐Rodrigues, T., Boia, R., Ferreira-Rodrigues, M., Girão, H., Ambrósio, A. F., & Santiago, A. R. (2021) · Biomolecules · doi:10.3390/biom11060770 · Cited by 61
Vandendriessche, C., Balusu, S., Van Cauwenberghe, C., Brkic, M., Pauwels, M., Plehiers, N., Bruggeman, A., Dujardin, P., Van Imschoot, G., Van Wonterghem, E., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01245-z · Cited by 56
“Further, it was shown that EVs isolated from the human AD brain, more specifically the temporal neocortex, contain more AβO and that these EVs can be responsible for the neuron-to-neuron transfer of AβO in vitro [31].”
BackgroundHuang, Y., Driedonks, T. A. P., Cheng, L., Turchinovich, A., Rajapaksha, H., Arab, T., Powell, B. H., Pletniková, O., Redding‐Ochoa, J., Troncoso, J. C., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220322 · Cited by 61
Wang, L., Zhang, X., Yang, Z., Wang, B., Gong, H., Zhang, K., Lin, Y., & Sun, M. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00453-6 · Cited by 59
Extracellular vesicles: translational research and applications in neurology
Manolopoulos, A., Yao, P. J., & Kapogiannis, D. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01080-z · Cited by 63
“Analysis of peptide subtypes revealed that NDEVs collected from either post-mortem Alzheimer disease brain tissue or serum from patients with Alzheimer disease had high Aβ 42 :Aβ 40 ratios 161,162 .”
Regulatory function of microRNAs in microglia
Brites, D. (2020) · Glia · doi:10.1002/glia.23846 · Cited by 56
“Furthermore, EVs are implicated in disease spreading of misfolded and pathological proteins, as well as in induction of proinflammatory signaling by miRNAs (Paolicelli, Bergamini, & Rajendran, 2019; Sardar Sinha et al., 2018) (Figure 3).”
BackgroundPérez‐González, R., Kim, Y., Miller, C., Pacheco‐Quinto, J., Eckman, E. A., & Levy, E. (2020) · The FASEB Journal · doi:10.1096/fj.202000823r · Cited by 52
Venkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 56
Leggio, L., L'Episcopo, F., Magrì, A., Ulloa‐Navas, M. J., Paternò, G., Vivarelli, S., Bastos, C. A. P., Tirolo, C., Testa, N., Caniglia, S., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201203 · Cited by 54
Insight into the Role of Extracellular Vesicles in Lysosomal Storage Disorders
Tancini, B., Buratta, S., Sagini, K., Costanzi, E., Delo, F., Urbanelli, L., & Emiliani, C. (2019) · Genes · doi:10.3390/genes10070510 · Cited by 54
“, Aβ peptide [68], APP fragments [69,70] and Tau [71], or PD, i.”
BackgroundAulston, B., Liu, Q., Mante, M., Florio, J., Rissman, R. A., & Yuan, S. H. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190656 · Cited by 54
“Recent hypotheses posit that extracellular vesicles (EVs) are mechanistically involved in disease propagation via cell to cell trafficking of infectious peptides, including tau [6] and Aβ [7].”
Extracellular vesicles: New horizons in neurodegeneration
Chen, J., Tian, C., Xiong, X., Yang, Y., & Zhang, J. (2025) · eBioMedicine · doi:10.1016/j.ebiom.2025.105605 · Cited by 53
Alzheimer’s Disease: A Molecular View of β-Amyloid Induced Morbific Events
Asik, R. M., Suganthy, N., Aarifa, M. A., Kumar, A., Szigeti, K., Máthé, D., Gulyás, B. Z., Archunan, G., & Padmanabhan, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091126 · Cited by 56
Dilna, A., Deepak, K. V., Damodaran, N., Kielkopf, C. S., Kagedal, K., Ollinger, K., & Nath, S. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166246 · Cited by 51
Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer’s Disease
Šála, M., Hollinger, K. R., Thomas, A. G., Dash, R. P., Tallon, C., Veeravalli, V., Lovell, L. E., Kögler, M., Hřebabecký, H., Procházková, E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00278 · Cited by 52
The multiple faces of extracellular vesicles released by microglia: Where are we 10 years after?
Gabrielli, M., Raffaele, S., Fumagalli, M., & Verderio, C. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.984690 · Cited by 61
Kodidela, S., Gerth, K. A., Haque, S., Gong, Y., Ismael, S., Singh, A. K., Ishrat, T., & Kumar, S. (2019) · Cells · doi:10.3390/cells8090968 · Cited by 51
“Gag Monocyte-derived macrophages [114] Brain tissues from AD patients [23] Astrocyte derived exosomes from plasma of AD patients [122]”
BackgroundInfluentialQuiroz-Baez, R., Hernández-Ortega, K., & Martínez-Martínez, E. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.580030 · Cited by 49
“In human brain sections from AD patients, the exosome marker flotillin-1 colocalizes with oligomers of Aβ (57).”
BackgroundMathew, B., Mansuri, M. S., Williams, K. R., & Nairn, A. C. (2021) · Brain Sciences · doi:10.3390/brainsci11020258 · Cited by 50
“Alternatively, exosomes could mediate the neuron-toglia or neuron-to-neuron transfer of toxic proteins [11,12].”
BackgroundNatale, F., Fusco, S., & Grassi, C. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00326-w · Cited by 54
Chatterjee, M., Özdemir, S., Kunadt, M., Koel‐Simmelink, M., Boiten, W., Piepkorn, L., Pham, T. V., Chiasserini, D., Piersma, S. R., Knol, J. C., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13066 · Cited by 47
“14 Transneu-ronal transfer by EVs was also reported for phosphorylated tau 15 and AD biomarkers A β 42, total tau (tTau) and phosphorylated tau (pTau) have been shown to be differentially expressed in CSF and plasma EVs derived from AD patients.”
BackgroundAβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease
Zhao, Y., Liu, B., Wang, J., Xu, L., Yu, S., Fu, J., Yan, X., & Su, J. (2022) · Biomedicines · doi:10.3390/biomedicines10081800 · Cited by 53
McAllister, B. B., Lacoursiere, S. G., Sutherland, R. J., & Mohajerani, M. H. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.01.026 · Cited by 54
Circulating extracellular vesicles: friends and foes in neurodegeneration
Calvani, R., Picca, A., Guerra, F., Coelho-Júnior, H. J., Bucci, C., & Marzetti, E. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320972 · Cited by 51
“Moreover, an uptake of isolated EVs containing Tau and Aβ oligomers has been observed in neuronal cultures (Asai et al., 2015; Sardar Sinha et al., 2018).”
InfluentialThe Neuroprotective and Neurodegeneration Effects of Heme Oxygenase-1 in Alzheimer’s Disease
Si, Z., & Wang, X. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200720 · Cited by 47
“The intraperitoneal or intracerebral injection of misfolded A (cid:2) extracted from AD brain or APP transgenic mice triggers cerebral amyloidosis, and evidence has revealed that amyloid pathology can spread from human-to-human [89, 90].”
Guo, Z. Y., Tang, Y., & Cheng, Y. C. (2022) · Current Drug Delivery · doi:10.2174/1567201819666220613150814 · Cited by 49
Neuropathology of the Alzheimer's continuum: an update
Jellinger, K. A. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3050 · Cited by 84
“However, recent findings have shown that the soluble form of APP binds directly to GABABR1a and modulates synaptic transmission [177], while that of Aβ aggregates do not need APP overexpression [178] but are performed by extracellular exosomes [173].”
BackgroundBrain Exosomes: Friend or Foe in Alzheimer’s Disease?
Kaur, S., Verma, H., Dhiman, M., Tell, G., Gigli, G. L., Janes, F., & Mantha, A. K. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02547-y · Cited by 48
Vassileff, N., Vella, L. J., Rajapaksha, H., Shambrook, M., Kenari, A. N., McLean, C., Hill, A. F., & Cheng, L. (2020) · Cells · doi:10.3390/cells9071709 · Cited by 49
Li, Z., Moniruzzaman, M., Dastgheyb, R. M., Yoo, S., Wang, M., Hao, H., Liu, J., Casaccia, P., Nogueras‐Ortiz, C. J., Kapogiannis, D., et al. (2020) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12035 · Cited by 54
“…spread neurotoxic proteins including Tau and Aβ (Baker et al., 2016; Crotti et al., 2019; Dinkins et al., 2016; Rajendran et al., 2006; Sardar Sinha et al., 2018), and lipids contained in EVs shed frommicrogliamay promote the extracellular formation of neurotoxic solubleAβ species…”
BackgroundInfluentialMesenchymal and Neural Stem Cell-Derived Exosomes in Treating Alzheimer’s Disease
Wang, H., Huber, C. C., & Li, X. (2023) · Bioengineering · doi:10.3390/bioengineering10020253 · Cited by 46
Beard, K., Meaney, D. F., & Issadore, D. (2020) · Journal of Neurotrauma · doi:10.1089/neu.2020.6990 · Cited by 44
Extracellular vesicle-associated lipids in central nervous system disorders
Vanherle, S., Haidar, M., Irobi, J., Bogie, J. F. J., & Hendriks, J. J. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.011 · Cited by 47
Extracellular Vesicle-Mediated Neuron–Glia Communications in the Central Nervous System
Ikezu, T., Yang, Y., Verderio, C., & Krämer‐Albers, E. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1170-24.2024 · Cited by 55
A novel and potent brain penetrant inhibitor of extracellular vesicle release
Rojas, C. J., Šála, M., Thomas, A. G., Chaudhuri, A. D., Yoo, S., Li, Z., Dash, R. P., Rais, R., Haughey, N. J., Nencka, R., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14789 · Cited by 46
“…2017), cancer metastasis (Kosaka et al., 2013), amyloid deposition (Dinkins et al., 2016; Dinkins, Dasgupta, Wang, Zhu, & Bieberich, 2014; Sardar Sinha et al., 2018), Tau protein propagation (Asai et al., 2015), and HIV infection (Barclay et al., 2017; Dalvi, Sun, Tang, & Pulliam, 2017; Hu et…”
Alix and Syntenin-1 direct amyloid precursor protein trafficking into extracellular vesicles
Cone, A. S., Hurwitz, S. N., Lee, G. S., Yuan, X., Zhou, Y., Li, Y., & Meckes, D. G. (2020) · BMC Molecular and Cell Biology · doi:10.1186/s12860-020-00302-0 · Cited by 48
Characterising Alzheimer's disease through integrative NMR- and LC-MS-based metabolomics
Nielsen, J. E., Maltesen, R. G., Havelund, J. F., Færgeman, N. J., Gotfredsen, C. H., Vestergård, K., Kristensen, S. R., & Pedersen, S. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100125 · Cited by 46
“Several studies have investigated their role in AD in relation to the spreading [21] and clearing [22] of amyloid-β (Aβ).”
BackgroundCurrent research status of blood biomarkers in Alzheimer’s disease: Diagnosis and prognosis
Feng, L., Li, J., & Zhang, R. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101492 · Cited by 47
Thomas, R. E., Vincow, E. S., Merrihew, G. E., MacCoss, M. J., Davis, M. Y., & Pallanck, L. J. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007694 · Cited by 42
Perrotte, M., Haddad, M., Le Page, A., Frost, E. H., Fulöp, T., & Ramassamy, C. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.10.010 · Cited by 41
Extracellular vesicles in Alzheimer’s disease: from pathology to therapeutic approaches
Thakor, A., & Garcia-Contreras, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.343882 · Cited by 41
“…accumulation of amyloid-β (Aβ) leading to Aβ plaque formation (Villemagne et al., 2018) and EVs isolated from the CSF have been shown to contain high levels of Aβ which is toxic to neurons cultured in vitro (Sardar Sinha et al., 2018) and in animal models in vivo (Elsherbini et al., 2020).”
BackgroundKim, Y., Pérez‐González, R., Miller, C., Kurz, M., D’Acunzo, P., Goulbourne, C. N., & Levy, E. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03701-1 · Cited by 81
“These include phosphorylated tau [45], A β oligomers [14, 15, 46] and α -synuclein preformed fibrils [47, 48].”
Pathogenic and therapeutic role of exosomes in neurodegenerative disorders
Huber, C. C., & Wang, H. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.375320 · Cited by 46
Haddad, M., Perrotte, M., Khedher, M. R. B., Demongin, C., Page, A. Y. L., Fülöp, T., & Ramassamy, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194906 · Cited by 44
Plasma microRNA vary in association with the progression of Alzheimer's disease
Guévremont, D., Tsui, H., Knight, R. G., Fowler, C. J., Masters, C. L., Martins, R. N., Abraham, W. C., Tate, W. P., Cutfield, N. J., & Williams, J. M. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12251 · Cited by 51
Rufino-Ramos, D., Lule, S., Mahjoum, S., Ughetto, S., Cristopher Bragg, D., Pereira de Almeida, L., Breakefield, X. O., & Breyne, K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121366 · Cited by 43
Biodegradable Mg alloy modified with bioactive exosomes for cardiovascular stent application
Hou, Y., Li, J., Cao, C. Q., Su, C., Qin, Z., Zhang, G., Guo, J., Tang, J., Zhang, J., & Guan, S. (2023) · Journal of Magnesium and Alloys · doi:10.1016/j.jma.2023.05.007 · Cited by 40
Molecular Mechanism of Autophagy: Its Role in the Therapy of Alzheimer’s Disease
Zhao, Y., Zhang, Y., Zhang, J., Zhang, X., & Yang, G. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200114163636 · Cited by 41
Martins, T. S., Magalhães, S., Rosa, I. M., Vogelgsang, J. S., Wiltfang, J., Delgadillo, I., Catita, J. A. M., Silva, O. A. B. D. C. E., Nunes, A., & Henriques, A. G. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191034 · Cited by 44
D’Arrigo, G., Gabrielli, M., Scaroni, F., Swuec, P., Amin, L., Pegoraro, A., Adinolfi, E., Virgilio, F. D., Cojoc, D., Legname, G., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12114 · Cited by 47
“Previous evidence in AD cellular models shows that small EVs storing misfolded proteins can be internalized and transferred between neurons through axonal projections (Sardar Sinha et al., 2018; Wang et al., 2017).”
BackgroundExtracellular Vesicles: Novel Roles in Neurological Disorders
Jin, Q., Wu, P., Zhou, X., Qian, H., & Xu, W. (2021) · Stem Cells International · doi:10.1155/2021/6640836 · Cited by 46
“Studies have also demonstrated that exosomes can transfer toxic Aβ and tau between neurons, resulting in neuron death and pathological protein propagation [57, 58].”
BackgroundYang, Z., Li, Y., & Wang, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030618 · Cited by 40
Small but Mighty—Exosomes, Novel Intercellular Messengers in Neurodegeneration
Kumari, M., & Anji, A. (2022) · Biology · doi:10.3390/biology11030413 · Cited by 47
“Most importantly, they were able to spread Aβ oligomers to other neurons, causing cytotoxicity [166].”
BackgroundUnveiling the Complex Role of Exosomes in Alzheimer’s Disease
Sun, M., & Chen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s466821 · Cited by 39
“18 These evidences suggest that exosomes have a role in the dissemination of tau and Aβ, which in turn leads to pathological damage in AD, when considered collectively.”
BackgroundThe Dichotomous Role of Extracellular Vesicles in the Central Nervous System
Graykowski, D. R., Wang, Y.-Z., Upadhyay, A., & Savas, J. N. (2020) · iScience · doi:10.1016/j.isci.2020.101456 · Cited by 39
Brain incoming call from glia during neuroinflammation: Roles of extracellular vesicles
D’Egidio, F., Castelli, V., d’Angelo, M., Ammannito, F., Quintiliani, M., & Cimini, A. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106663 · Cited by 46
“Recently, it has been reported that EVs isolated from AD patients are loaded with A β and able to propagate toxicity to other cells both in vitro and in vivo (Sardar Sinha et al., 2018; Elsherbini et al., 2020; Bodart-Santos et al., 2023).”
BackgroundExosomes as Mediators of Chemical-Induced Toxicity
Rokad, D., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2019) · Current Environmental Health Reports · doi:10.1007/s40572-019-00233-9 · Cited by 43
The emerging double-edged sword role of exosomes in Alzheimer’s disease
Liang, T., Wu, Z., Li, J., Wu, S., Shi, W., & Wang, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1209115 · Cited by 37
Bodart‐Santos, V., Pinheiro, L. S., da Silva‐Junior, A. J., Frozza, R. L., Ahrens, R., Gonçalves, R. A., Andrade, M. M., Chen, Y., Alcantara, C. D. L., Grinberg, L. T., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13134 · Cited by 43
“20,21 EVs derived from post mortem AD 11 brain and from a tauopathy mouse model 10 induce Tau phosphorylation in vivo.”
BackgroundCirculating exosomes repair endothelial cell damage by delivering miR‐193a‐5p
Cao, C. Q., Wang, B., Tang, J., Zhao, J., Guo, J., Guo, Q., Yue, X.-T., Zhang, Z., Liu, G., Zhang, H., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16202 · Cited by 38
Identification of amyloid beta in small extracellular vesicles via Raman spectroscopy
Imanbekova, M., Suarasan, S., Rojalin, T., Mizenko, R. R., Hilt, S., Mathur, M., Lépine, P., Nicouleau, M., Mohamed, N., Durcan, T. M., et al. (2021) · Nanoscale Advances · doi:10.1039/d1na00330e · Cited by 40
Visconte, C., Golia, M. T., Fenoglio, C., Serpente, M., Gabrielli, M., Arcaro, M., Sorrentino, F., Busnelli, M., Arighi, A., Fumagalli, G., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00746-0 · Cited by 36
Guo, M., Ge, X., Wang, C., Yin, Z., Jia, Z., Hu, T., Li, M., Wang, D., Han, Z., Wang, L., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13040639 · Cited by 37
“Studies have indicated that activated microglia promote the release of exosomes carrying misfolded proteins, such as α-synuclein, tau and beta-amyloid, in neurodegenerative diseases [7,46,47].”
BackgroundBacterial extracellular vesicles for gut microbiome–host communication and drug development
Qian, D., Xu, P., Wang, X., Du, C., Zhao, X., & Xu, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.008 · Cited by 41
“Investigations have isolated bacterial BEVs from human cerebrospinal fluid, associating them with the initiation and progression of neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) 89 .”
Wallin, C., Friedemann, M., Sholts, S. B., Noormägi, A., Svantesson, T., Jarvet, J., Roos, P. M., Palumaa, P., Gräslund, A., & Wärmländer, S. K. T. S. (2019) · Biomolecules · doi:10.3390/biom10010044 · Cited by 42
“The Aβ fibrils and plaques are the end-product of an Aβ aggregation process [37,39,40] involving extra- and/or intracellular formation of intermediate, soluble, and likely neurotoxic Aβ oligomers [41–44] that may transfer from neuron to neuron via exosomes [45,46].”
BackgroundEndosomal dysfunction impacts extracellular vesicle release: Central role in Aβ pathology
Arbo, B. D., Cechinel, L. R., Palazzo, R. P., & Siqueira, I. R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.101006 · Cited by 38
Flotillin: A Promising Biomarker for Alzheimer’s Disease
Angelopoulou, E., Paudel, Y. N., Shaikh, M. F., & Piperi, C. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020020 · Cited by 38
“Furthermore, another study has demonstrated that flotillin-1-positive exosomes isolated from postmortem brain sections of AD patients were highly enriched in toxic Aβ oligomers compared with healthy controls, which could be transferred into recipient’s cultured neurons [38].”
BackgroundLakshmi, S., Essa, M. M., Hartman, R. E., Guillemin, G. J., Sureshkumar, S., & Elumalai, P. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03111-1 · Cited by 37
Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression
Naser, S. S., Singh, D., Preetam, S., Kishore, S., Kumar, L., Nandi, A., Simnani, F. Z., Choudhury, A., Sinha, A., Mishra, Y. K., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100701 · Cited by 43
Vestuto, V., Conte, M., Vietri, M., Mensitieri, F., Santoro, V., Muro, A. D., Alfieri, M., Moros, M., Miranda, M. R., Amante, C., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479959 · Cited by 38
Yamoah, A., Tripathi, P., Sechi, A. S., Köhler, C. N., Guo, H., Chandrasekar, A., Nolte, K. W., Wruck, C. J., Katona, I., Anink, J. J., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190722 · Cited by 38
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2021) · Biomolecules · doi:10.3390/biom11070980 · Cited by 35
“In particular, BDEs from Alzheimer’s patients contain Aβ and hyperphosphorylated tau, two hallmarks of AD brains [27].”
BackgroundExosomes as drug delivery vehicles and biomarkers for neurological and auditory systems
Mittal, R., Bencie, N., Langlie, J. A., Mittal, J., & Eshraghi, A. A. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30484 · Cited by 37
“Additionally, oligomer spread was decreased once exosomes were blocked, indicating exosomes could be used as drug delivery systems or as biomarkers in neurological diseases, such as Alzheimer's disease (Sardar Sinha et al., 2018).”
Background“Prion-like” seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders
Zampar, S., Gregorio, S. E. D., Grimmer, G., Watts, J. C., & Ingelsson, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1436262 · Cited by 42
Self-citationTissue-derived extracellular vesicles: Research progress from isolation to application
Qin, B., Hu, X., Su, Z., Zeng, X.-B., Ma, H., & Xiong, K. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153604 · Cited by 35
Recent Insights into the Neurobiology of Alzheimer’s Disease and Advanced Treatment Strategies
Anitha, K., Singh, M. K., Kohat, K., Varshini, T. S., Chenchula, S., Padmavathi, R., Amerneni, L. S., Vishnu Vardhan, K., Mythili Bai, K., Chavan, M. R., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04384-1 · Cited by 42
“Studies have demonstrated that exosomal proteins such as flotillin-1 and Alix accumulate around amyloid plaques in the AD brain [44].”
Griffin, E. F., Yan, X., Caldwell, K. A., & Caldwell, G. A. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy308 · Cited by 37
Sil, S., Singh, S., Chemparathy, D. T., Chivero, E. T., Gordon, L., & Buch, S. J. (2021) · Aging and Disease · doi:10.14336/ad.2021.0406 · Cited by 33
“play key roles in various neurodegenerative diseases, such as Alzheimer’s Disease [39], Parkinson’s disease [40], Amyotrophic Lateral Sclerosis [41] as well as HIVassociated neurocognitive disorders (HAND) [42].”
BackgroundGao, S., Jia, S., Bai, L., Li, D., & Meng, C. (2022) · Cells · doi:10.3390/cells11243956 · Cited by 34
“At present, polarized microglia are known to release exosomes containing proteins related to neurodegenerative diseases, such as α-synuclein [17], cytokines [18], Aβ [19], and tau [20]; however, the effects of microglia exosomes on ferroptosis of neuronal cells remain unclear.”
BackgroundRussell, J. C., Merrihew, G. E., Robbins, J. E., Postupna, N. O., Kim, T.-K., Golubeva, A., Noori, A., Wang, K., Keene, C. D., MacCoss, M. J., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00204-1 · Cited by 34
“There is evidence that such EV-mediated spreading may be important during Alzheimer’s disease (Pluta et al. 2018; Sardar Sinha et al. 2018), and large EV “exophers” are produced by aged nematodes (Melentijevic et al. 2017).”
BackgroundGabrielli, M., Tozzi, F., Verderio, C., & Origlia, N. (2022) · Cells · doi:10.3390/cells12010063 · Cited by 36
Su, W., Wang, Y., Shao, S., & Ye, X. (2024) · Brain and Behavior · doi:10.1002/brb3.3503 · Cited by 33
Role of Exosomes in Cancer-Related Cognitive Impairment
Koh, Y. Q., Tan, C. J., Toh, Y. L., Sze, S. K., Ho, H. K., Limoli, C. L., & Chan, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082755 · Cited by 34
“Amyloid beta and tau deposition in the brain has been identified as a toxic event by which exosome mediates to impair synaptic structure and function in Alzheimer’s disease [69], while the progressive accumulation of α-synuclein in the brain through exosomes has been linked to Parkinson’s disease [50,70].”
BackgroundSimpson, L. W., Szeto, G. L., Boukari, H., Good, T. A., & Leach, J. B. (2020) · ACS Omega · doi:10.1021/acsomega.0c02046 · Cited by 32
Ren, Y., Ge, K., Sun, D., Hong, Z., Jia, C., Hu, H., Shao, F., & Yao, B. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113870 · Cited by 34
Endothelial Senescence and Its Impact on Angiogenesis in Alzheimer’s Disease
Georgieva, I., Tchekalarova, J. D., Iliev, D. B., & Tzoneva, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411344 · Cited by 32
Extracellular Vesicles in Neurodegenerative Diseases: An Update
Sigdel, S., Swenson, S., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713161 · Cited by 31
Pathogenic and protective roles of extracellular vesicles in neurodegenerative diseases
Takeuchi, T. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa131 · Cited by 31
Dhakal, S., Ramsland, P. A., Adhikari, B., & Macreadie, I. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179456 · Cited by 30
“Recent studies supporting increased amyloid content in AD brains and the fact that diseased neurons release exosomes with oligomeric forms of Aβ42 from neurons which spread to the neighbouring neurons has been found to be crucial for AD progression [22,23].”
BackgroundCano, A. C., Antonio, E. E., Bernuz, M., Puerta, R., García‐González, P., de Rojas, I., Olivé, C., Pérez‐Cordón, A., Montrreal, L., Núñez‐Llaves, R., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01793-7 · Cited by 33
Guix, F. X. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24526 · Cited by 32
“However, the capacity of exosomes to bind small toxic oligomers may also contrib‐ ute to their propagation in the brain and spreading their toxic effects (Sardar Sinha et al., 2018).”
Background
Metadata
- Authors
- Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M.
- Affiliations
- Linköping University (SE)
- Uppsala University (SE)
- Corresponding author
- Hallbeck, Martin
- Venue
- Acta Neuropathologica
- Published
- 2018-06-13
- Volume
- 136
- Issue
- 1
- Pages
- 41-56
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC6015111
- OpenAlex
- W2807776100
- Cited by
- 527
- References
- 60
- Citations by year
- 2026: 48 · 2025: 70 · 2024: 71 · 2023: 64 · 2022: 60 · 2021: 74 · 2020: 82 · 2019: 50 · 2018: 6
- FWCI
- 36.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Funders
- Vetenskapsrådet (523-2013-2735)
- Alzheimerfonden
- Hjärnfonden
- Hans-Gabriel och Alice Trolle Wachtmeister Stiftelse för Medicinsk forskning
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Knut och Alice Wallenbergs Stiftelse
- Demensförbundet
- Linköpings Universitet
- Region Östergötland
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, exosomes, amyloid-beta oligomers, prion-like propagation, extracellular vesicles, tau pathology, exosome secretion, exosome uptake, neurotoxicity
- MeSH terms
- Tsg101 Protein, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cell Line, Transformed, DNA-Binding Proteins, Female, Gene Expression Regulation, Humans, L-Lactate Dehydrogenase, Male, Membrane Proteins, Middle Aged, Neuroblastoma, Organic Chemicals, Peptide Fragments, Transcription Factors, Amyloid beta-Peptides, Culture Media, Conditioned, Coculture Techniques, Protein Transport, Pluripotent Stem Cells, Microscopy, Electron, Transmission, Exosomes, Endosomal Sorting Complexes Required for Transport
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.